Anti‐desmoglein‐2 autoantibodies do not discriminate between UK boxer dogs with and without arrhythmogenic right ventricular cardiomyopathy
Veterinary Record · 28.03.2026 · 198 (7)
DOI: 10.1002/vetr.6014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Record, online erschienen am 06.12.2025. Verfasst von Chia-Hsuan Chang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Veterinary School, University of Bristol, Langford, UK. Hauptthemen laut MEDLINE: Dog Diseases, Autoantibodies, Arrhythmogenic Right Ventricular Dysplasia, Desmoglein 2. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BSAVA PetSavers (CRP 6.19), The Bristol Veterinary School Research Activity Fund.
Abstract (Originalsprache)
Background
Evidence regarding the diagnostic utility of serum anti‐desmoglein‐2 (DSG2) autoantibodies for arrhythmogenic right ventricular cardiomyopathy (ARVC) in boxer dogs is conflicting.
Methods
Prospective standardised evaluation of apparently healthy boxer dogs for ARVC was performed at three referral centres, including blood pressure measurement, electrocardiography, echocardiography, haematology, biochemistry (including cardiac troponin I) and 24‐hour Holter monitoring. Additional dogs with a diagnosis of ARVC were retrospectively recruited. ARVC disease status was defined using cut‐offs of 20 or less (unaffected) and more than 300 (affected) ventricular premature complexes of right ventricular origin in 24 hours. The residual serum samples were stored at ‒80°C for analysis for anti‐DSG2 autoantibodies using ELISA techniques.
Results
Forty boxer dogs were enrolled (11 healthy controls, 10 with preclinical ARVC and 19 with clinical ARVC). Serum anti‐DSG2 autoantibodies were detected in all dogs, bar one healthy dog. DSG2 differed significantly between groups ( p = 0.031) and was significantly lower in dogs with preclinical versus clinical ARVC ( p = 0.025).
Limitations
Some data were collected retrospectively, and some dogs were receiving antiarrhythmic therapy.
Conclusion
Serum DSG2 autoantibodies can be present in boxer dogs with preclinical and clinical ARVC and apparently healthy controls.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bristol Veterinary School, University of Bristol, Langford, UK.
- Langford Vets, University of Bristol, Langford, UK.
- Labatt Family Heart Centre, The Hospital for Sick Children & Research Institute, University of Toronto, Toronto, Ontario, Canada.
- Department of Small Animal Clinical Science, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Neston, UK.
ORCID-Profile: Kieran Borgeat, Hannah Hodgkiss-Geere, Joanna Dukes-McEwan, Robert Hamilton, Melanie J Hezzell
Förderung
- BSAVA PetSavers (CRP 6.19)
- The Bristol Veterinary School Research Activity Fund
Zitieren
APA
Chang, C. H., Watson, C., Chatterjee, D., Ward, J., Borgeat, K., Hodgkiss-Geere, H., Dukes-McEwan, J., Hamilton, R., & Hezzell, M. J. (2026). Anti‐desmoglein‐2 autoantibodies do not discriminate between UK boxer dogs with and without arrhythmogenic right ventricular cardiomyopathy. Veterinary Record, 198(7). https://doi.org/10.1002/vetr.6014
Vancouver
Chang CH, Watson C, Chatterjee D, Ward J, Borgeat K, Hodgkiss-Geere H, et al. Anti‐desmoglein‐2 autoantibodies do not discriminate between UK boxer dogs with and without arrhythmogenic right ventricular cardiomyopathy. Veterinary Record. 2026;198(7). doi:10.1002/vetr.6014
BibTeX
@article{Chang2026,
author = {Chang, Chia-Hsuan and Watson, Claire and Chatterjee, Diptendu and Ward, Jade and Borgeat, Kieran and Hodgkiss-Geere, Hannah and Dukes-McEwan, Joanna and Hamilton, Robert and Hezzell, Melanie J},
title = {Anti‐desmoglein‐2 autoantibodies do not discriminate between UK boxer dogs with and without arrhythmogenic right ventricular cardiomyopathy},
journal = {Veterinary Record},
year = {2026},
volume = {198},
number = {7},
doi = {10.1002/vetr.6014}
}
EUVIMED